292 related articles for article (PubMed ID: 24717260)
1. Toward understanding ubiquitin-modifying enzymes: from pharmacological targeting to proteomics.
Lill JR; Wertz IE
Trends Pharmacol Sci; 2014 Apr; 35(4):187-207. PubMed ID: 24717260
[TBL] [Abstract][Full Text] [Related]
2. Deubiquitinases and the new therapeutic opportunities offered to cancer.
Pfoh R; Lacdao IK; Saridakis V
Endocr Relat Cancer; 2015 Feb; 22(1):T35-54. PubMed ID: 25605410
[TBL] [Abstract][Full Text] [Related]
3. Targeting the ubiquitin pathway for cancer treatment.
Liu J; Shaik S; Dai X; Wu Q; Zhou X; Wang Z; Wei W
Biochim Biophys Acta; 2015 Jan; 1855(1):50-60. PubMed ID: 25481052
[TBL] [Abstract][Full Text] [Related]
4. Use of proteome arrays to globally identify substrates for E3 ubiquitin ligases.
Persaud A; Rotin D
Methods Mol Biol; 2011; 759():215-24. PubMed ID: 21863490
[TBL] [Abstract][Full Text] [Related]
5. Enzyme-substrate relationships in the ubiquitin system: approaches for identifying substrates of ubiquitin ligases.
O'Connor HF; Huibregtse JM
Cell Mol Life Sci; 2017 Sep; 74(18):3363-3375. PubMed ID: 28455558
[TBL] [Abstract][Full Text] [Related]
6. Deubiquitinases (DUBs) and DUB inhibitors: a patent review.
Farshi P; Deshmukh RR; Nwankwo JO; Arkwright RT; Cvek B; Liu J; Dou QP
Expert Opin Ther Pat; 2015; 25(10):1191-1208. PubMed ID: 26077642
[TBL] [Abstract][Full Text] [Related]
7. Deubiquitinating enzyme inhibitors and their potential in cancer therapy.
Crosas B
Curr Cancer Drug Targets; 2014; 14(6):506-16. PubMed ID: 25088039
[TBL] [Abstract][Full Text] [Related]
8. Targeting HECT-type E3 ligases - insights from catalysis, regulation and inhibitors.
Fajner V; Maspero E; Polo S
FEBS Lett; 2017 Sep; 591(17):2636-2647. PubMed ID: 28771691
[TBL] [Abstract][Full Text] [Related]
9. H2A-DUBbing the mammalian epigenome: expanding frontiers for histone H2A deubiquitinating enzymes in cell biology and physiology.
Belle JI; Nijnik A
Int J Biochem Cell Biol; 2014 May; 50():161-74. PubMed ID: 24647359
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting the deubiquitinating enzymes (DUBs).
Ndubaku C; Tsui V
J Med Chem; 2015 Feb; 58(4):1581-95. PubMed ID: 25364867
[TBL] [Abstract][Full Text] [Related]
11. Targeting Ferroptosis by Ubiquitin System Enzymes: A Potential Therapeutic Strategy in Cancer.
Meng Y; Sun H; Li Y; Zhao S; Su J; Zeng F; Deng G; Chen X
Int J Biol Sci; 2022; 18(14):5475-5488. PubMed ID: 36147464
[TBL] [Abstract][Full Text] [Related]
12. Deubiquitylase Inhibition Reveals Liver X Receptor-independent Transcriptional Regulation of the E3 Ubiquitin Ligase IDOL and Lipoprotein Uptake.
Nelson JK; Cook EC; Loregger A; Hoeksema MA; Scheij S; Kovacevic I; Hordijk PL; Ovaa H; Zelcer N
J Biol Chem; 2016 Feb; 291(9):4813-25. PubMed ID: 26719329
[TBL] [Abstract][Full Text] [Related]
13. Regulation of proteolysis by human deubiquitinating enzymes.
Eletr ZM; Wilkinson KD
Biochim Biophys Acta; 2014 Jan; 1843(1):114-28. PubMed ID: 23845989
[TBL] [Abstract][Full Text] [Related]
14. The demographics of the ubiquitin system.
Clague MJ; Heride C; Urbé S
Trends Cell Biol; 2015 Jul; 25(7):417-26. PubMed ID: 25906909
[TBL] [Abstract][Full Text] [Related]
15. Proteomics strategy to identify substrates of LNX, a PDZ domain-containing E3 ubiquitin ligase.
Guo Z; Song E; Ma S; Wang X; Gao S; Shao C; Hu S; Jia L; Tian R; Xu T; Gao Y
J Proteome Res; 2012 Oct; 11(10):4847-62. PubMed ID: 22889411
[TBL] [Abstract][Full Text] [Related]
16. Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer.
Pal A; Young MA; Donato NJ
Cancer Res; 2014 Sep; 74(18):4955-66. PubMed ID: 25172841
[TBL] [Abstract][Full Text] [Related]
17. Chemical biology tools to study Deubiquitinases and Ubl proteases.
Gorka M; Magnussen HM; Kulathu Y
Semin Cell Dev Biol; 2022 Dec; 132():86-96. PubMed ID: 35216867
[TBL] [Abstract][Full Text] [Related]
18. Role of the ubiquitin proteasome system in hematologic malignancies.
Sahasrabuddhe AA; Elenitoba-Johnson KS
Immunol Rev; 2015 Jan; 263(1):224-39. PubMed ID: 25510280
[TBL] [Abstract][Full Text] [Related]
19. Riding the DUBway: regulation of protein trafficking by deubiquitylating enzymes.
Millard SM; Wood SA
J Cell Biol; 2006 May; 173(4):463-8. PubMed ID: 16702236
[TBL] [Abstract][Full Text] [Related]
20. Proteomics-Based Identification of DUB Substrates Using Selective Inhibitors.
Bushman JW; Donovan KA; Schauer NJ; Liu X; Hu W; Varca AC; Buhrlage SJ; Fischer ES
Cell Chem Biol; 2021 Jan; 28(1):78-87.e3. PubMed ID: 33007217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
